Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022

Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its second-quarter 2022 financial and operational results on August 4, 2022, before market opening. A conference call and webcast will take place at 8:30 am ET to discuss these results and provide a business update. Interested parties can join through a toll-free number or via the company's website. Aurinia, headquartered in Victoria, British Columbia, is focused on therapies for serious diseases, notably its FDA-approved oral treatment, LUPKYNIS® (voclosporin), for lupus nephritis.

Positive

• Aurinia's LUPKYNIS® (voclosporin) is the first FDA-approved oral therapy for lupus nephritis, indicating strong market potential.
• The scheduled conference call shows transparency and commitment to keeping investors informed.

Negative

• None.

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Interested participants can dial 877-407-9170 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005597/en/

Investor and Corporate

DeDe Sheel, VP, Investor Relations

aurinia@westwicke.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

When will Aurinia Pharmaceuticals release its Q2 2022 financial results?

Aurinia Pharmaceuticals will release its Q2 2022 financial results on August 4, 2022.

What is the purpose of the conference call on August 4, 2022?

The conference call will review Aurinia's financial results and provide a general business update.

What is LUPKYNIS®?

LUPKYNIS® is the first FDA-approved oral therapy for adult patients with active lupus nephritis, developed by Aurinia Pharmaceuticals.

How can I access the Aurinia Pharmaceuticals conference call?

Participants can dial 877-407-9170 or access the audio webcast on Aurinia's corporate website.